Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
about
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenAromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenPharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trialA simple, selective and rapid validated method for estimation of anastrazole in human plasma by liquid chromatography-tandem mass spectrometry and its application to bioequivalence study.Estrogenic upregulation of DNA polymerase beta in oocytes of preovulatory ovine follicles.Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkersAltering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors.Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase.Pharmacology and clinical experience with exemestane.An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole.Effects of age on the detection and management of breast cancer.Third-generation aromatase inhibitors in the treatment of advanced breast cancer.The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuumAnastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor.Multiple structural and functional abnormalities in the p450 aromatase expressing transgenic male mice are ameliorated by a p450 aromatase inhibitor.Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell deathAromatase inhibitors for treatment of postmenopausal patients with breast cancer.Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.Safety issues surrounding the use of aromatase inhibitors in breast cancer.Inhibition of estradiol synthesis attenuates renal injury in male streptozotocin-induced diabetic rats.Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.Coagulopathic complications in breast cancer.The use of high dose letrozole in ovulation induction and controlled ovarian hyperstimulationAromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?Do female sex hormones initiate breast cancer? A review of the evidence.Skeletal health in postmenopausal survivors of early breast cancer.The discovery and mechanism of action of letrozole.Aromatase inhibitors in the treatment of early and advanced breast cancer.Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trialThe therapeutic potential of novel aromatase inhibitors in breast cancer.Bone loss and the aromatase inhibitorsEffects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC studyManagement of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.
P2860
Q24239985-0091A9BF-B762-4925-BB6D-EB1A64CAB970Q24246391-715437E5-421D-4895-BBE2-D69023ACC984Q28345359-FE6342B5-9BE9-48F0-82E3-05249CF8929EQ30883132-33226AFB-A1A5-479F-B3E2-641A0324724AQ32163504-6E354FBA-7E9F-44EF-91F8-B2C7D4EB13D1Q33793932-A3913E4F-B772-4694-BE9E-CC96D0BE1CA9Q33830320-5227E9F6-482A-4441-BCA5-B82602530C09Q33871478-95EA73E6-9F1A-4D17-837C-D04DA8490B69Q33917551-74E6148F-A0CA-4431-844C-73AE01F8BB6EQ33937883-3E7D01C1-8254-4355-871C-6FFB293FC854Q34075034-DC75143A-1C43-45CE-BFEB-DD4A8DEAFFCEQ34156603-7AD1ED59-02BA-420C-9D51-463411977F2DQ34298801-EFA449AD-9338-4CD2-8FA3-7837766E2955Q34477879-B5C4018C-C53D-490E-9629-ADBD7F2F85B3Q34494011-D542F0DC-FCCA-423E-BD1F-C0512096D221Q34592879-26935AC7-4ECC-44A7-81B5-B60296C4E373Q34733910-EDDA1D41-5124-4A72-A304-745E935DB00FQ34745884-100B2700-DE29-4059-8977-EE40AE2CC77BQ35034811-604B069B-DCD7-4D9D-B5B9-BEF7FADD0FD2Q35095538-4B647F9C-3B97-4A74-A78D-870B20D56F59Q35096084-CEF6FD21-0ED2-46C3-8316-59ADC8ED11A9Q35107727-5858A2A9-2B80-4354-BC08-FC38436DFF09Q35117738-0469AA99-DC45-40AD-B9CE-D2795B10980CQ35118969-08D8A195-A290-4FBD-BC96-B36DC83C520AQ35194446-2FA7DC66-1F82-4220-B0CA-1A98FC4B1CB6Q35216784-C0026292-39C1-4AF5-8DD2-DC351D222A07Q35273689-0ABED09F-494A-4C33-959F-260A3ED59BDBQ35554561-79713896-7F77-447D-BB7E-493CDCB0941FQ35608886-FF2253DB-F259-4370-943C-885392F18F82Q35738998-DF8CEC85-85CA-41AE-8CE6-AD31BC01AAC8Q35776951-BCA1B4CA-50CE-4765-AF78-4D380E56F5DBQ35924752-D074E29D-E1F5-4E4F-810C-2D7DDBBA54B7Q36006750-412D6F12-487B-45D5-A41A-4B197077251EQ36026408-DE432759-F1E1-41E8-B60A-01D1D169AF9FQ36105220-3C2E22DA-2A84-41DA-95F3-7A7774B36E22Q36162366-69B1F937-E75D-4752-B51E-AD6650E30D30Q36181280-452589BD-F138-489E-8253-650762B262C8Q36229440-C0FA85C6-DC1C-468D-8E23-BB5475C1C6EEQ36245589-3EB645F1-B07E-4A06-B6B0-FC36F32C79E0Q36274927-A5D5DD63-BEA3-4391-B9E7-980E79745351
P2860
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Influence of anastrozole (Arim ...... usal women with breast cancer.
@ast
Influence of anastrozole (Arim ...... usal women with breast cancer.
@en
type
label
Influence of anastrozole (Arim ...... usal women with breast cancer.
@ast
Influence of anastrozole (Arim ...... usal women with breast cancer.
@en
prefLabel
Influence of anastrozole (Arim ...... usal women with breast cancer.
@ast
Influence of anastrozole (Arim ...... usal women with breast cancer.
@en
P2093
P2860
P356
P1476
Influence of anastrozole (Arim ...... usal women with breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1996.531
P407
P577
1996-10-01T00:00:00Z
P5875
P6179
1024344066